MARKET

EYES

EYES

Second Sight Med
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.8699
0.0000
0.00%
Closed 16:00 10/20 EDT
OPEN
0.8700
PREV CLOSE
0.8699
HIGH
0.8700
LOW
0.8571
VOLUME
49.78K
TURNOVER
--
52 WEEK HIGH
7.60
52 WEEK LOW
0.6906
MARKET CAP
20.11M
P/E (TTM)
-0.5083
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Second Sight Medical Products Inc. Announces Resumption of Its Early Feasibility Study of the Orion® Cortical Visual Prosthesis at UCLA
Second Sight Medical Products Inc. (NASDAQ: EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the resumption of its Early Feasibility Study of the Orion® Visual Cortical
Business Wire · 09/22 13:00
Second Sight Medical Products Announces Resumption Of Its Early Feasibility Study Of The Orion Cortical Visual Prosthesis At UCLA
Second Sight Medical Products Inc. Announces Resumption of Its Early Feasibility Study of the Orion® Cortical Visual Prosthesis at UCLA Second Sight Medical Products Inc. (NASDAQ:EYES), a developer, manufacturer and
Benzinga · 09/22 12:17
EYES, SOLO, FOSL and VAL among midday movers
Seeking Alpha - Article · 06/09 16:45
M, OPK among premarket gainers
Seeking Alpha - Article · 06/09 13:16
Second Sight Medical Products (EYES) Upgraded to Buy: Here's What You Should Know
Second Sight Medical Products (EYES) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks · 06/03 16:00
Second Sight Medical Products (EYES) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Zacks · 05/13 17:30
Second Sight Medical Products Inc. Announces Closing of Public Offering of Common Stock
Business Wire · 05/05 18:08
Second Sight Medical Products Announces The Closing Of Common Stock Offering Of 7.5 Million Shares At $1 Per Share
Benzinga · 05/05 17:09
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EYES. Analyze the recent business situations of Second Sight Med through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EYES stock price target is 2.500 with a high estimate of 2.500 and a low estimate of 2.500.
EPS
Institutional Holdings
Institutions: 56
Institutional Holdings: 1.95M
% Owned: 8.43%
Shares Outstanding: 23.12M
TypeInstitutionsShares
Increased
4
58.88K
New
7
-29.32K
Decreased
7
60.92K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.25%
Healthcare Equipment & Supplies
+0.08%
Key Executives
Chairman/Director
Gregg Williams
Chief Executive Officer/Director
Matthew Pfeffer
Vice President - Operations
Ted Randolph
Vice President
Edward Randolph
Other
Stephen Okland
Director
Jonathan McGuire
Independent Director
Aaron Mendelsohn
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About EYES
Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company intends to develop Orion Visual Cortical Prosthesis which provides useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease or forms of cancer and trauma. Its product, The Argus II Retinal Prosthesis System (The Argus II) provides electrical stimulation of the retina to induce visual perception in blind individuals and helps in treating outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. The Company's Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Second Sight Medical Products Inc stock information, including NASDAQ:EYES real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EYES stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EYES stock methods without spending real money on the virtual paper trading platform.